Testing a nasal spray to help secondary progressive MS patients

This trial is testing foralumab, a medication given as a nasal spray, to see if it can help slow or improve symptoms in people with secondary progressive multiple sclerosis (a form of MS where the disease gradually worsens over time). The study will measure whether the medication is safe and whether it reduces brain inflammation and improves fatigue. You would only be eligible if you have already completed an earlier foralumab study.

Secondary progressive MS causes slow, steady worsening of symptoms, and current treatments have limited effects on this form of the disease. Researchers believe this medication might work by reducing inflammation in the brain and immune system in a new way—through the nose—which could help slow disease progression and improve quality of life.